Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
Original-Research

Emerald Horizon AG (von NuWays AG): BUY 11.11.2026, 09:00 Uhr von EQS Research Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Emerald Horizon 1.120,00 EUR -0,44 % Lang & Schwarz
Kostenlose Aktienchance per SMS Ausgewählte Trading-Einschätzungen aufs Handy.

Original-Research: Emerald Horizon AG - from NuWays AG

11.11.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to Emerald Horizon AG

Company Name: Emerald Horizon AG
ISIN: AT0000A3UZE1
 
Reason for the research: Update
Recommendation: BUY
Target price: EUR 1,300
Target price on sight of: 12 months
Last rating change:
Analyst: Jorge Gonzalez

€ 135m equity plan could pave the way for institutional funding

Emerald Horizon plans to raise c. € 135m through up to five capital increases by Q3 2028, compared with our previous estimate of € 72m through YE 2028. The initial subscription price of c. € 1,013 represents an 11.9% discount to Monday's closing price (€ 1,150). Importantly, CEO and majority shareholder Florian Wagner (52.9% stake) offers investors subscribing at least € 5m an additional 36 shares per 100 subscribed, transferred from his personal holdings after a 36-month holding period. Available for binding commitments before the initial € 45m subscription threshold is reached, this implies an effective entry price of c. € 745 per share, a 35.2% discount to Monday's close, without additional dilution. Note that Mr Wagner has already pledged € 20m in equity contributions over 2026–2028. Proceeds will support ADES development with VDL Groep and the equity component of DUALstore deployments.

A more clearly defined equity financing plan could improve Emerald's prospects for EIB financing. In our view, the announced programme could strengthen Emerald's positioning to secure financing from the European Investment Bank (EIB). In September, the EIB committed up to € 40m to Finnish nuclear developer Steady Energy, its first SMR financing, through an InvestEU-backed long-term convertible loan supporting research, testing and licensing of its LDR-50 reactor. Although technologically different from Emerald's subcritical thorium concept, the transaction illustrates the EIB's willingness to support early-stage nuclear development. Comparable financing could offer attractive long-term conditions but potentially require a substantial upfront equity contribution. Importantly, EIB participation would also represent a significant endorsement, helping de-risk ADES and reducing the need for a rapid commercial ramp-up of DUALstore (BESS + TESS) to materially lower the group's risk profile.

Institutional funding could help bridge substantial development requirements. Our previous € 72m equity assumption covered the first two ADES Test Loops and the equity component of initial storage deployments. However, gross funding requirements reach c. € 225m through 2030, before potential grants, including storage deployments, ADES Test Loops and demonstrators. Emerald has previously identified potential Slovak investment incentives of € 75–100m, a € 100m bank debt facility under discussion and potential EU funding programmes. Against this backdrop, the announced equity financing plan could facilitate complementary institutional funding and improve visibility over the development roadmap. Nevertheless, the Steady Energy precedent does not establish Emerald's eligibility for comparable EIB support.

Limited valuation impact, potentially meaningful financing catalyst. Incorporating the announced € 135m equity financing programme has a negligible impact on our DCF-based PT. Successful execution could nevertheless strengthen Emerald's financial position and improve visibility over its development roadmap. Potential EIB participation would represent a meaningful financing and credibility catalyst, although execution, financing and regulatory risks remain material. BUY, PT € 1,300 unchanged.

You can download the research here: emerald-horizon-ag-2026-11-11-update-en-153f9
For additional information visit our website: https://www.nuways-ag.com/research

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2432310  11.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer